Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10510726" target="_blank" >RIV/00064165:_____/25:10510726 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wuYX.8s9n2" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wuYX.8s9n2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41408-025-01444-0" target="_blank" >10.1038/s41408-025-01444-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Popis výsledku v původním jazyce

Lower-risk (LR) myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by ineffective hematopoiesis, abnormal blood cell development, and a relatively low risk of progression to acute myeloid leukemia or death [1]. Anemia is a hallmark of LR-MDS and often leads to chronic red blood cell (RBC) transfusion dependence (TD), which is a reflection of further bone marrow failure, increased disease burden, and shortened survival ( ~ 3–9 years) [1, 2]. These patients present with a clinical challenge, in that the primary therapeutic goal is to improve the cytopenias and manage their symptoms (typically through supportive care and targeted pharmacotherapeutics) rather than controlling the malignant hematopoiesis [3,4,5]. There is an unmet need for improvements in therapies for LR-MDS that can target the underlying cause of the disease.

Název v anglickém jazyce

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Popis výsledku anglicky

Lower-risk (LR) myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by ineffective hematopoiesis, abnormal blood cell development, and a relatively low risk of progression to acute myeloid leukemia or death [1]. Anemia is a hallmark of LR-MDS and often leads to chronic red blood cell (RBC) transfusion dependence (TD), which is a reflection of further bone marrow failure, increased disease burden, and shortened survival ( ~ 3–9 years) [1, 2]. These patients present with a clinical challenge, in that the primary therapeutic goal is to improve the cytopenias and manage their symptoms (typically through supportive care and targeted pharmacotherapeutics) rather than controlling the malignant hematopoiesis [3,4,5]. There is an unmet need for improvements in therapies for LR-MDS that can target the underlying cause of the disease.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Cancer Journal

ISSN

2044-5385

e-ISSN

2044-5385

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

217

Kód UT WoS článku

001651935000002

EID výsledku v databázi Scopus

2-s2.0-105026349169